ADVANCES IN ADJUVANT THERAPY FOR RESECTED NON SMALL CELL LUNG CANCER

Đỗ Kim Quế 1 , , Trần Mạnh Hoàng 1 , Đỗ Duy Anh 1
1 Thong Nhat Hospital
* Corresponding author:

Article Information

Metrics
Downloads: 0 Views: 0
DOI
10.63947/bvtn.v1i2.3
Published
2025-06-15
Issue Vol. 1 No. 2 (2025): Aging Population and Healthcare Challenges
Section
Review
Categories
Research

Download Article

PDF (Vietnamese)

How to Cite

1.
Kim Quế Đỗ, Mạnh Hoàng T, Duy Anh Đỗ. ADVANCES IN ADJUVANT THERAPY FOR RESECTED NON SMALL CELL LUNG CANCER. JHA [Internet]. Vietnam; 2025 Jun. 15 [cited 2025 Jun. 23];1(2):34–41. https://tcsuckhoelaohoa.vn/bvtn/article/view/34 doi: 10.63947/bvtn.v1i2.3
Loading citation...
Crossref
Scopus
Google Scholar
Europe PMC

Abstract

Non Small Cell Lung Cancer (NSCLC) is the second most common cancer in both sex but it is still the leading cause of cancer death. Most of NSCLN appear in the late stage so the prognosis is very poor. Although, the patient in early stage NSCLC who underwent standard lobectomy but the recurrent rate is still so high. Adjuvant therapy after standard surgical therapy gives the patient better overall survival (OS) and disease Free Survival (DFS). Recent advances in diagnosis and treatment for NSCLC show the benefit of adjuvant therapy with TKI or Immunotherapy for selected NSCLC patients.

Keywords

Non Small Cell Lung Cancer Adjuvant therapy

References

  1. Rami-Porta R, Wittekind C, Goldstraw P. Complete resection in lung cancer surgery: proposed definition. Lung cancer (Amsterdam, Netherlands). 2005;49(1):25-33
  2. Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(1):29-34.
  3. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. The Lancet Oncology. 2006;7(9):719-727.
  4. Booth CM, Shepherd FA, Peng Y, et al. Time to adjuvant chemotherapy and survival in non-small cell lung cancer: a population-based study. Cancer. 2013;119(6):1243-1250.
  5. Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(19):2998-3006.
  6. Wang EH, Corso CD, Rutter CE, et al. Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33(25):2727-2734.
  7. Le Pechoux C, Pourel N, Barlesi F, et al. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial. The Lancet Oncology. 2022;23(1):104-114.
  8. Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet (London, England). 2021;398(10308):1344-1357.
  9. O'Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. The Lancet Oncology. 2022;23(10):1274-1286.
  10. Zhong WZ, Wang Q, Mao WM, et al. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021;39(7):713-722.
  11. Solomon BJ, Ahn JS, Dziadziuszko R, et al. LBA2 ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC). Annals of Oncology. 2023;34:S1295-S1296.
  12. Herbst RS, Wu YL, John T, et al. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023;41(10):1830-1840.

License

© 2025 Journal of Health and Aging - Thong Nhat Hospital

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.